Skip to main content
Premium Trial:

Request an Annual Quote

Center for Molecular Medicine, Xceed Molecular, Arrayjet, BlueGnome, Colorado Genetics Laboratory, Cytogenetics and Molecular Cytogenetics Laboratory, University of South Florida, Tampa, Oklahoma Center for the Advancement of Science and Technology, Oklah

Premium
Center for Molecular Medicine Joins Xceed’s Strategic Collaborator Program
 
Xceed Molecular this week announced that the Center for Molecular Medicine has joined its newly launched Strategic Collaborator program, a “mutually beneficial agreement” designed to propel the partners’ clinical research, while providing Xceed with additional real-world clinical-laboratory experience and access to critical research results.
 
Xceed, which launched its Ziplex array platform this month, said in a statement that the program is an integral part of its strategy to add assays to its pipeline of condition- or pathway-specific Signature Chips that will be available both as catalog products and through Xceed’s Expression Services.
 
Through the program, Xceed will provide its Ziplex System or Expression Services to the collaborator at no or low cost in return for a commitment for future publication, access to biomarker content, or assistance with product development or services.

Xceed said that it has already committed to several other institutions under its Strategic Collaborator program and will be installing the Ziplex System at additional sites before year-end. The company’s goal is to have 10 Strategic Collaborator agreements in North America by the second quarter of 2008.

 

 
Arrayjet Workforce Grows 30 Percent
 
Arrayjet said this week that it has expanded its workforce by 30 percent due to an uptick in the market for arrayers.
 
According to Duncan Hall, the firm’s commercial director, all areas of Arrayjet’s business have “felt the positive impact of a buoyant market” and the company has added to its applications group as well as production capability.
 
An Arrayjet spokesperson told BioArray News this week that the firm currently employs 13 people, with 9 involved with applications and production and four in commercial.
 

 
Two US Genetics Labs Using BlueGnome's CytoChip Platform for ArrayCGH Analysis
 
BlueGnome said recently that two US genetics labs are now using its CytoChip platform in arrayCGH analysis of DNA samples.
 
The Colorado Genetics Laboratory and the Cytogenetics and Molecular Cytogenetics Laboratory at the University of South Florida, Tampa, are now using the array technology.
 
Financial terms of the agreement were not released.
 

 
Oklahoma Univ. Lab Awarded $300K Grant
 
Oklahoma Center for the Advancement of Science and Technology has decided to award $300,000 to the Liyou Wu Lab in Oklahoma University’s Institution for Environmental Genomics, OCAST said last week.
 
According to OCAST, the funding will be matched by the US Department of Energy’s GTL Genomics Program. Wu’s project is for developing microarray technology for analysis of microbial organisms.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.